WaferGen Signs Distribution Agreements for SmartSlide™ Micro-Incubation System in Australia, Singapore and the Benelux
News Feb 06, 2008
WaferGen Biosystems, Inc. has announced the signing of exclusive distribution agreements for the company's SmartSlide™ Micro-Incubation System with INBIO in Australia, ScienceWerke Pte. Ltd. in Singapore and Westburg B.V. in the Benelux countries (Belgium, the Netherlands and Luxemborg).
Each of the distributor agreements, which cover WaferGen's entire family of SmartSlide Micro-Incubation System products, is renewable contingent on the achievement of target milestones.
INBIO, ScienceWerke and Westburg are distributors of products and services to cell biologists and stem cell researchers in the life science markets within their geographic areas of focus.
WaferGen's SmartSlide Micro-Incubation System is a family of integrated fluidics exchange micro-incubation products that work with inverted microscopes. This technology is enabling cell biology and stem cell researchers to conduct complex time lapse imaging studies to characterize, differentiate and proliferate cells, as well as grow stem, primary and other difficult to cultivate cells in consistently optimal physiological conditions. As a result, this system is allowing researchers to conduct their work smarter, faster and less expensively than with current equipment, the company says.
"WaferGen's signing of these key distributor agreements represents an important step in the company's strategic efforts to expand customer adoptions of the SmartSlide Micro-Incubation System into new large target markets," said Alnoor Shivji, WaferGen's chairman and chief executive officer. "We are happy to bring the critical performance advantages of the SmartSlide Micro-Incubation System to researchers in Australia, Singapore and the Benelux."
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018